STOCK TITAN

Tonix Pharmaceuticals Holding Corp - TNXP STOCK NEWS

Welcome to our dedicated news page for Tonix Pharmaceuticals Holding (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tonix Pharmaceuticals Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tonix Pharmaceuticals Holding's position in the market.

Rhea-AI Summary
Tonix Pharmaceuticals presents positive data on mTNX-1700 in treating colorectal cancer at CICON23 conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals presents data on the proposed mechanism of TNX-1900 in treating chronic migraine at the 2023 International Headache Congress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.52%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
Rhea-AI Summary
Tonix Pharmaceuticals commits to meeting potential increased demand for Tosymra nasal spray 10 mg after GlaxoSmithKline discontinues Imitrex nasal spray 5 mg and 20 mg products in January 2024. Tonix is prepared to alleviate potential shortages in sumatriptan, a widely used treatment for acute migraine. Intranasal sumatriptan is recommended for patients with severe nausea or vomiting during attacks. Tosymra is differentiated from generic equivalents due to its proprietary absorption enhancer technology, providing quick pain relief in as little as 10 minutes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Tonix Pharmaceuticals announces topline results from Phase 2 study of TNX-102 SL for fibromyalgia-type Long COVID
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
clinical trial covid-19
-
Rhea-AI Summary
Tonix Pharmaceuticals to commence Phase 1/2 clinical trial for TNX-801 vaccine after receiving FDA feedback
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
none
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announced that its Chief Medical Officer will present at the August 2023 Virtual Investor Summit. Tonix is a biopharmaceutical company focused on developing therapeutics for various diseases. Its lead candidate, TNX-102 SL, is in mid-Phase 3 development for fibromyalgia. Tonix also has candidates for major depressive disorder, rare diseases, immunology, and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Tonix Pharmaceuticals has initiated a Phase 1 study of TNX-1500, a biologic candidate for the prevention of kidney transplant rejection and other transplant and autoimmune disorders. The study aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of TNX-1500 in healthy volunteers. TNX-1500 has shown promise in animal studies, preventing organ rejection and preserving graft function. The initiation of this study supports dosing in a planned Phase 2 trial in kidney transplant recipients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
-
Rhea-AI Summary
Tonix Pharmaceuticals Holding Corp. announced financial results for Q2 2023 and provided an overview of recent operational highlights. The company completed enrollment in four clinical trials for CNS indications and expects to release topline results for fibromyalgia, fibromyalgia-type Long COVID, chronic migraine, and depression before the end of 2023. Tonix also completed the acquisition of two acute migraine products, Zembrace SymTouch and Tosymra, which generated approximately $30 million in sales for the past year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
covid-19
Tonix Pharmaceuticals Holding Corp

Nasdaq:TNXP

TNXP Rankings

TNXP Stock Data

15.53M
84.49M
0.01%
19.85%
1.7%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Chatham

About TNXP

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.